A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients - A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2629-2635

  Wang, Fu Bin ^a   Yang, Xue Qin ^b   Yang, Shuo ^a   Wang, Bi Cheng ^c   Feng, Mao Hui ^b   Tu, Jian Cheng ^a  

^a WUHAN UNIVERSITY   (China)

^b JINGCHU UNIVERSITY OF TECHNOLOGY   (China)

^c ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Analysis; Circulating tumor cells; Meta; Prognosis; Prostate cancer

Indexed keywords

EID: 84863255318     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Allan AL, Keeney M (2010). Circulating tumor cell analysis: technical and statistical considerations for spplication to the clinic. J Oncol, 2010, 426218.
2. Allen D, Butt A, Cahill D, et al (2004). Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci, 1022, 76-80.
3. Ashworth TR (1999). A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J, 14, 146-49.
4. Baker SG, Kramer BS(2003). A perfect correlate does not a surrogate make. BMC Medical Research Methodology, 3, 16.
5. Bastian PJ, Palapattu GS, Yegnasubramanian S, et al (2007). Prognostic Value of Preoperative SerumCell-Free Circulating DNA in Men with Prostate Cancer Under going Radical Prostatectomy. Clin Cancer Res, 13, 5361-67.
6. Berruti A, Mosca A, Tucci M, et al (2005). Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocrine-Related Cancer, 12, 109-17.
7. Budd GT, Cristofanilli M, Eills Mj, et al(2006). Circulating tumor cells versus imaging predicting overall survival in metastatic breast cancer. Clin Cancer Res, 12, 6403-9.
8. Burzykowski T, Buyse M (2006). Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat, 5, 173-86.
9. Buyse M, Molenberghs G, Burzykowski T, et al (2000). The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics, 1, 49-67.
10. Carey RW, Taft PD, Bennett JM, et al (1976). Carcinocythemia (carcinoma cell leukemia): an acute leukemia-like picture due to metastatic carcinoma cells. Am J Med, 60, 273-8.
11. Cristofanilli M, Budd GT, Eills Mj, et al (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 351, 781-94.
12. Cristofanilli M, Hayes DF, Budd GT, et al (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol, 23, 1420-30.
13. Danila DC, Heller G, Gignac GA, et al (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res, 13,7053-58.
14. Davis JW, Nakanishi H, Kumar VS, et al (2008). Circulating tumor celld in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol, 179, 2187-91.
15. de Bono JS, Scher HI, Montgomery RB, et al(2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res, 14, 6302-9.
16. de la Taille A, OlssonCA, Buttyan R, et al (1999). Columbia university experience of detection of circulating cells by RT-PCR PSA in prostate cancer as a predictive factor of stage and biochemical recurrence. Prog Urol, 9, 555-61.
17. de la Taille A, Salomon L, Colombel M, et al(1999). Detection of circulating prostatic cells with RT-PCR PSA in prostatic cancer. Prog Urol, 9, 1084-9.
18. Egger M, Davey SG. Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
19. Fehm T, Sagalowsky A, Clifford E, et al (2002). Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res, 8, 2073-84.
20. Hara SM, Moreno JG, Zweitzig DR, et al (2004). Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem, 50, 826-35.
21. Helo P, Cronin AM, Danila DC, et al (2009). Circulating prostate tumor cells detected by Reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem, 55, 765-73.
22. Ignatiadis M, Georgoulias V, Mavroudis D (2008). Micrometastatic disease in breast cancer: Clinical implications. Eur J Cancer, 44, 2726-36.
23. Kelly WK, Sher HI, Mazumdar M, et al (2003). Prostate-specific antigen as measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol, 11, 607-15.
24. Lobodasch K, Fröhlich F, Rengsberger M, et al (2007). Quantification of circulating tumor cells for the monitoring of adjuvant therapy in breast cancer: An increase in cell number at completion of therapy is a predictor of early relapse. The Breast, 16, 211-8.
25. Millon R, Jacqmin D, Muller D, et al (1999). Detection of prostate-specific antigen or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: Clinical implications. Eur Urol, 36, 278-85.
26. Mocellin S, Hoon D, Ambrosi A, et al (2006). The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis. Clin Cancer Res, 12, 4605-13.
27. Moreno JG, Hara SM, Gross S, et al (2001).Changes in circulating carcinoma cells in metastatic prostate cancer patients correlates with disease status. Urology, 58, 386-92.
28. Moreno JG, Miller MC, Gross S, et al (2005). Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology, 65, 713-8.
29. Mudan S, Giakoustidis A, Thillainayagam AV, et al(2010). Clinical utility of circulating tumor cell measurement in the diagnosis of indeterminate lesions of pancreas. Future Oncology, 6, 177-9.
30. Olmos D, Arkenau HT, Ang JE, et al (2009). Circulating tumor cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol, 20, 27-33.
31. Rahbari NN, Aigner M, Thorlund K, et al (2010). Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology, 138, 1714-26.
32. Shen CX, Hu L, Xia L, et al (2009). The detection of circulating tumor cells of breast cancer patients by using multi-marker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem, 42, 194-200.
33. Sleijfer s, Gratama JW, Sieuwerts AM, et al (2007). Circulating tumor cell detection on its way to routine diagnostic implementation. Eur J Cancer, 43,2645-50.
34. Stewart LA, Clarke MJ, on behalf of the Cochrane Working Party Group on Meta-analysis using Individual Patient Data (1995). Practical methodology of meta-analyses (overviews) using updated individual patient data. Statistics in Medicine, 14, 2057-79.
35. Stewart LA, Parmar MK (1993). Meta-analysis of literature or of individual patient data. Lancet, 341, 418-22.
36. Stott SL, Lee RJ, Nagrath S, et al (2010). Isolation and characterization of circulating tumor cell from patients with localized and metastatic prostate cancer. Sci Transl Med, 2, 25ra23.
37. Tibbe AGJ, Miller MC, Terstappen LW (2007). Statistical considerations for enumeration of circulating tumor cells. Cytometry A, 71, 154-62.
38. Wang ZP, Eisenberger MA, Carducci MA, et al (2000). Identification and characterization of circulating prostate carcinoma cells. Cancer, 88, 2787-95.